Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
NCCN Guidelines: Making Shared Decisions in Metastatic TNBC
December 15th 2021As part of its CURE Speaking Out video series, CURE spoke with Dr. Rebecca Moroose, from Orlando Health Cancer Institute, and Dr. Virginia G. Kaklamani, from UT Health San Antonio, about shared-decision making with the NCCN Guidelines on metastatic triple-negative breast cancer.
Study Confirms Adding Ibrance to Endocrine Therapy May Not Improve Outcomes in Early Breast Cancer
December 8th 2021The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
Discussing Hereditary Cancer, VHL Disease With One’s Family
November 2nd 2021As a part of its “Speaking Out” video series, CURE spoke with Stacy Lloyd on behalf of the VHL Alliance, about discussing hereditary cancer with family members and how a diagnosis can lead to earlier surveillance for the disease.
Adding Darzalex to Standard of Care May Improve Survival in Newly Diagnosed Multiple Myeloma
June 22nd 2021Results from a recent study strongly support a treatment regimen of Darzalex with Revlimid and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.
Fotivda Nearly Doubles Duration of Response Compared With Nexavar in Metastatic Kidney Cancer
June 6th 2021In patients with metastatic renal cell carcinoma whose disease failed to respond to two prior therapies, Fotivda, compared with Nexavar, contributed to a duration of response of 20.3 months versus 9 months.